Nav: Home

Colorectal cancer: Combined analysis enhances risk prediction

February 26, 2018

If first-degree relatives are affected by colorectal cancer, this indicates a person's own elevated risk of developing bowel cancer. The same holds true for people who have large numbers of genetic risk markers in their genome. Both factors are usually used alternatively, not combined, to predict risk. Scientists from the German Cancer Research Center (DKFZ) in Heidelberg have now shown that a combination of family history and an analysis of genetic markers helps determine a person's colorectal cancer risk more precisely.

When the conversation is about colon cancer screening, physicians often ask their patients about cancer cases among close family members. Colorectal cancer in first-degree relatives is considered a known risk factor for the disease. Besides family history, a person's profile of genetic risk markers also provides information about his or her personal cancer risk. This scientific term refers to very small gene variants (called single nucleotide polymorphisms), each of which, taken on its own, has only minimal relation to the probability of suffering disease. Taken together, however, they have a significant impact.

"It is a widely held notion that genetic risk profile and family history essentially both provide the same, redundant information," says Hermann Brenner, an expert for colorectal cancer prevention from the DKFZ. In a current study, Brenner has now modified this concept and has proven that it is beneficial to use both information sources in combination.

Korbinian Weigl, an epidemiologist who is the first author of the study, analyzed the family history and, in a parallel effort, a panel of 53 known genetic risk markers in approximately 4,500 participants of the DACHS* study. About half of the cases studied were colorectal cancer patients. Weigl discovered that the two factors deliver largely independent results:
  • The risk for disease in participants with colorectal cancer cases in first-degree relatives was about twice as high as that of participants with no family history of bowel cancer.

  • The risk for disease in the group of participants with the largest numbers of genetic risk markers in their genomes was three times higher than that of study participants with the smallest numbers of risk variants.

  • The risk in participants with a positive family history who also display numerous genetic risk markers multiplied: Colorectal cancer is six times as prevalent in them as in people who have no family history of bowel cancer and exhibit only small numbers of risk markers in their genomes.

  • No significant association was found between the numbers of genetic risk variants and family history.


"People often assume that familial colorectal cancer is primarily related to genetic predisposition," Brenner said. "This is true in a small proportion of colorectal cancer cases, particularly those with onset at early age." However, in the majority of colorectal cancer cases, this is not the case. Brenner thinks this might be due to the fact that cancer cases in the family primarily reflect common non-genetic factors such as smoking or a physically inactive lifestyle.

In addition, large numbers of genetic risk markers increase the risk of developing cancer in people with and without a family history of bowel cancer alike.

"The result clearly shows us that the combination of both factors has the potential to make risk prediction for colorectal cancer significantly more precise," Brenner sums up. "The more accurately we can predict a person's risk, the better we can adjust preventive measures. For people with high risks, for example, it would be beneficial to start colorectal cancer screening much earlier than at age 50."
-end-
The DACHS study is an epidemiological case-control study of the German Cancer Research Center (DKFZ). DACHS is an abbreviation for "Darmkrebs: Chancen der Verhütung durch Screening" (Colorectal cancer: chances for prevention through screening). DACHS is one of the largest population-based case-control studies worldwide. For more information see also: http://dachs.dkfz.org/dachs/

Korbinian Weigl, Jenny Chang-Claude, Phillip Knebel, Li Hsu, Michael Hoffmeister, Hermann Brenner: Strongly enhanced colorectal cancer risk stratification by combining family history and genetic risk score. Clinical Epidemiology 2018, DOI: 10.2147/CLEP.S145636

A picture is available for download: http://www.dkfz.de/de/presse/pressemitteilungen/2018/bilder/Fotolia_139480276_L.jpg

Note on use of images related to press releases

Use is free of charge. The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) permits one-time use in the context of reporting about the topic covered in the press release. Images have to be cited as follows: "Yodiyim, Fotolia"

Distribution of images to third parties is not permitted unless prior consent has been obtained from DKFZ's Press Office (phone: ++49-(0)6221 42 2854, E-mail: presse@dkfz.de). Any commercial use is prohibited.

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic. In the German Consortium for Translational Cancer Research (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.

German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)

Related Colorectal Cancer Articles:

New method for early screening of colorectal cancer
A highly sensitive method that can detect even the earlier stages of colorectal cancer has been developed by researchers in Japan.
Adults with disabilities screened less often for colorectal cancer
Colorectal cancer is the fourth most common type of cancer in the United States, with nearly 135,000 cases reported in 2016.
Colorectal cancer statistics, 2017
Despite dramatic reductions in overall colorectal cancer incidence and mortality, striking disparities by age, race, and tumor subsite remain
Gene mutations among young patients with colorectal cancer
While many patients with colorectal are diagnosed when they are older than 50, about 10 percent of patients are diagnosed at younger ages.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
New immunotherapy study at Sanford centers on colorectal cancer
Sanford Health has opened another clinical trial exploring the power of the body's immune system to fight cancer.
UA Cancer Center team questions safety, efficacy of selenium and colorectal cancer risk
Selenium has been a popular nutritional supplement for decades, touted for its antioxidant properties and its role in stopping free radicals from damaging cells and DNA.
How mouth microbes may worsen colorectal cancer
Bacteria commonly found in the mouth have been recently shown to worsen colorectal cancer in animals, but it has not been clear how these microbes make their way to the gut in the first place.
Pretargeted radioimmunotherapy may eliminate colorectal cancer
An emerging cancer therapy has colorectal tumors surrounded. Presenters at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging are unveiling a novel radioimmunotherapy that combines a cancer-seeking antibody with potent radionuclide agents, resulting in complete remission of colorectal cancer in mouse models.
As colorectal cancer rate falls, diagnosis of late-stage cancer in young patients is up
University of Colorado Cancer Center study presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2016 finds that in patients over 50, the rate of CRC is falling at 2.5 percent per year while the rate of CRC in patients under 50 is rising at 0.8 percent per year.

Related Colorectal Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Bias And Perception
How does bias distort our thinking, our listening, our beliefs... and even our search results? How can we fight it? This hour, TED speakers explore ideas about the unconscious biases that shape us. Guests include writer and broadcaster Yassmin Abdel-Magied, climatologist J. Marshall Shepherd, journalist Andreas Ekström, and experimental psychologist Tony Salvador.
Now Playing: Science for the People

#514 Arctic Energy (Rebroadcast)
This week we're looking at how alternative energy works in the arctic. We speak to Louie Azzolini and Linda Todd from the Arctic Energy Alliance, a non-profit helping communities reduce their energy usage and transition to more affordable and sustainable forms of energy. And the lessons they're learning along the way can help those of us further south.